about
Urinary N telopeptide levels in predicting the anti-nociceptive responses of zoledronic acid and paclitaxel in a rat model of bone metastases.Zoledronate suppressed angiogenesis and osteogenesis by inhibiting osteoclasts formation and secretion of PDGF-BBPanobinostat synergizes with zoledronic acid in prostate cancer and multiple myeloma models by increasing ROS and modulating mevalonate and p38-MAPK pathways.Bisphosphonate related osteonecrosis of the jaws: a review.Models for anti-tumor activity of bisphosphonates using refined topochemical descriptors.
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 13 May 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Pharmacokinetic evaluation of zoledronic acid.
@en
Pharmacokinetic evaluation of zoledronic acid.
@nl
type
label
Pharmacokinetic evaluation of zoledronic acid.
@en
Pharmacokinetic evaluation of zoledronic acid.
@nl
prefLabel
Pharmacokinetic evaluation of zoledronic acid.
@en
Pharmacokinetic evaluation of zoledronic acid.
@nl
P2093
P2860
P50
P1476
Pharmacokinetic evaluation of zoledronic acid
@en
P2093
Amelia D'Alessio
Francesco Perrone
Luana Lamura
Maria Pergameno
Monica Rosaria Maiello
Pasqualina Giordano
P2860
P304
P356
10.1517/17425255.2011.585156
P407
P577
2011-05-13T00:00:00Z